Paracrine Regulation of BPH Pathogenesis

BPH 发病机制的旁分泌调节

• 批准号: 8477178
• 负责人: Simon W Hayward
• 金额: $ 30.92万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-04-15 至 2015-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8477178
• 关键词: Acute; Address; Adrenergic Antagonists; Adrenergic Receptor; Adult; Androgens; Benign; Benign Prostatic Hypertrophy; Bladder; Bone Marrow; Cells; Cessation of life; Chemoprevention; Chronic; Clinical; Combined Modality Therapy; Creatinine; Cyclooxygenase Inhibitors; Data; Development; Differentiation and Growth; Disease; Dutasteride; Epithelial; Epithelial Cells; Estrogens; Ethers; Finasteride; Frequencies; Goals; Growth; Health Care Costs; Human; Hyperplasia; Inflammation; Inflammatory; Inflammatory Response; Kidney Failure; Lead; Left; Life; Link; Longitudinal Studies; Modeling; Molecular; Morbidity - disease rate; Mus; NF-kappa B; National Institute of Diabetes and Digestive and Kidney Diseases; Nocturia; Nuclear; Oxidoreductase; Pathogenesis; Pathway interactions; Patients; Plant Roots; Play; Population; Process; Prostaglandin-Endoperoxide Synthase; Prostate; Prostatic; Prostatic Epithelium; Prostatic Stroma; Prostatic hypertrophy; Publishing; Recommendation; Regulation; Research; Rofecoxib; Role; Serum; Signal Pathway; Signal Transduction; Smooth Muscle; Strategic Planning; Stromal Change; Symptoms; Therapeutic; Up-Regulation; Urethra; Urinary Retention; Urinary tract infection; Western World; Work; cell type; chemokine; constriction; cytokine; fetal; improved; inhibitor/antagonist; macrophage; male; novel strategies; novel therapeutic intervention; overexpression; paracrine; prostatitis; public health relevance; response; tumor; urinary

DESCRIPTION (provided by applicant): Benign prostatic hyperplasia (BPH) is an important cause of orbidity in the adult male population and is the most common symptomatic tumor-like condition in humans. Clinically BPH results in urethral constriction with a consequent slowing of urinary flow rates and an inability to properly empty the urinary bladder. In the Western world BPH is not a life threatening condition. However, it is a condition with significant associated morbidity and consequent healthcare costs. BPH results in a variety of problems including nocturia, frequency, urgency and post-mictural dribbling and, more seriously it can cause renal insufficiency (with rising serum creatinine), frequent urinary tract infections and urosepsis due to insufficient urinary draining. For many decades the core of research into BPH has centered around androgen and estrogen signaling. These studies have given rise to the development of 51-reductase inhibitors such as finasteride and dutasteride. However these directions have not shown much recent progress in developing new approaches to improve the situation of patients. New concepts are sorely needed to move the field forwards. The central hypothesis of this proposal is that prostatic inflammation results in a profile of stromal changes which contribute to focal benign glandular expansion. The long term goal of this work is to identify pathways which can be co-targeted ether alone as a form of chemoprevention or along with current standard BPH therapies to provide safe and long term symptomatic relief. This proposal addresses a number of the high priority recommendations of the recently published NIDDK Prostate Research Strategic Plan including; the creation of new models; the development of an understanding of the signaling, interaction and crosstalk between multiple cell types in the prostate; and, the characterization of disease-relevant cellular pathways for potential therapeutic applications. The three specific aims in this proposal address interlocking aspects of BPH pathogenesis. The first aim looks at the effects of inflammatory cytokine expression on prostatic epithelial and stromal differentiation. The second aim examines the consequences of these changes in relation to the recruitment of bone marrow- derived cell populations and the contribution that these play in hyperplastic growth. The third aim examines the targeting of nuclear factor-kappa B as a strategy to influence BPH pathogenesis.

描述（由申请人提供）：良性前列腺增生（BPH）是成年男性人口孤立的重要原因，并且是人类最常见的症状肿瘤状况。临床上的BPH导致尿道收缩，因此尿流速的减慢，无法正确排空膀胱。在西方世界，BPH并不是威胁生命的状况。但是，这是一种具有显着关联的发病率和随之而来的医疗保健成本的疾病。 BPH导致多种问题，包括夜尿，频率，紧迫性和骨气后运球，更认真地导致肾脏不足（血清肌酐的增加），频繁的尿路感染以及由于尿液不足而导致的尿尿素。数十年来，对BPH的研究的核心一直围绕雄激素和雌激素信号传导。这些研究导致了51个还原酶抑制剂（例如非那雄胺和杜达雄胺）的发展。但是，这些方向在开发新方法以改善患者状况方面并未显示出太大的进展。迫切需要新概念来向前移动该领域。该提议的中心假设是前列腺炎症会导致基质变化的特征，从而有助于局灶性良性腺体膨胀。这项工作的长期目标是识别可以单独将醚共同靶向的途径作为化学预防的一种形式，也可以与当前的标准BPH疗法一起提供安全且长期的症状缓解。该提案涉及最近发表的NIDDK前列腺研究战略计划的许多高优先级建议，包括：创建新模型；对前列腺中多种细胞类型之间的信号，相互作用和串扰的理解的理解。以及针对潜在治疗应用的疾病相关的细胞途径的表征。该提案中的三个特定目的涉及BPH发病机理的互锁方面。第一个目的着眼于炎性细胞因子表达对前列腺上皮和基质分化的影响。第二个目的研究了这些变化在募集骨髓衍生细胞群体以及这些变化对增生生长中的贡献的后果。第三个目标将核因子-kappa B的靶向作为影响BPH发病机理的策略。